Assessment of Early Radiation Oncology Involvement Alongside Standard Oncologic Care in the Managemet

Inclusion criteria

• ✓. Age ≥ 18 years
• ✓. Zubrod performance status 0-2
• ✓. Pathology-proven cancer, with primary site outside of the central nervous system
• ✓. Clinical (based on physical exam or imaging) or pathological diagnosis of metastatic disease, for which curative intent treatment is not feasible and treatment goals are palliative. Both patients with newly diagnosed metastatic disease, and those who have a metastatic relapse after prior curative-intent treatment for their malignancy, are eligible.
• ✓. Estimated life expectancy 6-24 months. Guidelines for estimating life expectancy will be based on best available evidence, based primarily on tumor type, systemic therapy used and its expected outcome, line of systemic therapy, and in some cases patients' initial response to systemic therapy, along with the enrolling medical oncologist's judgement.
• ✓. Either planned, or actively receiving, systemic therapy (chemotherapy, targeted/biologic therapy, immunotherapy, or hormonal therapy)
• ✓. Ability to understand and the willingness to sign a written informed consent document
• ✓. If a patient is actively participating in another clinical trial utilizing an investigation agent, they are still eligible for participation in this study unless radiation therapy is explicitly not allowed in that trial.